DRUG SAFETY ASSESSMENT IN CLINICAL TRIALS: CONCEPTS AND ISSUES

被引:1
|
作者
Nautiyal, Naveen [1 ]
Rastogi, Rajul [1 ]
Gamperl, Hans-Joachim [1 ]
机构
[1] Fresenius Kabi Oncol Ltd, Global Vigilance, Gurgaon 122001, Haryana, India
关键词
Pharmacovigilance; Adverse Event; Adverse Drug Reactions; Clinical Trial; Drug Safety;
D O I
10.13040/IJPSR.0975-8232.6(10).4159-67
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ensuring patient safety during and after clinical trials is the sole priority of the drug-development process. In both clinical trials and clinical practice, each patient must be treated according to his or her illness and needs. For this purpose, monitoring of patient safety at all levels of drug-development is given utmost importance. Such monitoring is a dynamic process having motive of protecting trial volunteers and patients from preventable harm during and after clinical trials respectively. For this purpose, knowledge of the basics of drug safety at all levels is essential especially for the healthcare professionals. Many literatures have been published on drug safety and clinical trials but a systemic document focusing strictly on all the dimensions is lacking. In this article, we have discussed upon all aspects of drug safety in clinical trials including the basics of drug safety, patient suitability for safety in trials, regulatory aspects of drug safety, causality, risk assessment and post marketing safety of the drug products.
引用
收藏
页码:4159 / 4167
页数:9
相关论文
共 50 条
  • [31] Equivalence concepts in clinical trials
    V. W. Steinijans
    M. Neuhäuser
    F. Bretz
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2000, 25 : 38 - 40
  • [32] Equivalence concepts in clinical trials
    Steinijans, VW
    Neuhäuser, M
    Bretz, F
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2000, 25 (01) : 38 - 40
  • [33] Priority safety data issues in late phase clinical trials: A qualitative approach from an academic clinical trials unit
    Wills, Genevieve Helen
    Arenas-Pinto, Alejandro
    Dunn, David
    Goodall, Ruth
    [J]. TRIALS, 2019, 20
  • [34] WHAT IS AN ANTIARRHYTHMIC DRUG - FROM CLINICAL-TRIALS TO FUNDAMENTAL-CONCEPTS
    NATTEL, S
    WATERS, D
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (01): : 96 - 99
  • [35] A Kinetic Model for the Integrated Assessment of Safety and Efficacy in Clinical Trials
    Diamond, George A.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (09): : 1456 - 1463
  • [36] Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module update
    Lassere, MND
    Johnson, KR
    Boers, M
    Carlton, K
    Day, RO
    de Wit, M
    Edwards, IR
    Fries, JF
    Furst, DE
    Kirwan, JR
    Tugwell, PS
    Woodworth, TG
    Brooks, PM
    [J]. JOURNAL OF RHEUMATOLOGY, 2005, 32 (10) : 2037 - 2041
  • [37] Cardiovascular Function in Nonclinical Drug Safety Assessment: Current Issues and Opportunities
    Sarazan, R. Dustan
    Mittelstadt, Scott
    Guth, Brian
    Koerner, John
    Zhang, Joanne
    Pettit, Syril
    [J]. INTERNATIONAL JOURNAL OF TOXICOLOGY, 2011, 30 (03) : 272 - 286
  • [38] Clinical issues in the assessment of adolescent alcohol and other drug use
    Winters, KC
    Latimer, WW
    Stinchfield, R
    [J]. BEHAVIOUR RESEARCH AND THERAPY, 2002, 40 (12) : 1443 - 1456
  • [39] ASSESSMENT OF ADVERSE DRUG-REACTIONS IN CLINICAL-TRIALS
    PETRIE, WM
    LEVINE, J
    [J]. INTERNATIONAL PHARMACOPSYCHIATRY, 1978, 13 (04): : 209 - 216
  • [40] Outcomes assessment of drug treatment in multiple sclerosis clinical trials
    Malone, M
    Lomaestro, B
    [J]. PHARMACOECONOMICS, 1996, 9 (03) : 198 - 210